It is highlighted that oxidative stress contributes to inflammation, metabolic dysfunction, and cellular damage during disease progression and may be exacerbated by interventions associated with gene therapy—including vector-induced immune activation, transgene-related cellular stress, and delivery-associated tissue injury.
Abstract
Inherited retinal degenerations (IRDs) are a genetically heterogeneous group of disorders characterized by progressive loss of photoreceptors and retinal pigment epithelium, leading to irreversible vision impairment. Although gene therapy has transformed the therapeutic outlook for IRDs, its efficacy remains limited by gene and variant specificity, a narrow treatment window dependent on viable target cells, and the persistence of retinal degeneration even after restoration of gene function. In this review, we summarize current gene-based therapeutic strategies, critically examine oxidative stress as a shared but heterogeneous downstream mechanism across IRDs, and review antioxidant and redox-modulating interventions with particular emphasis on the distinction between preclinical and clinical evidence. This review highlights that oxidative stress contributes to inflammation, metabolic dysfunction, and cellular damage during disease progression and may be exacerbated by interventions associated with gene therapy—including vector-induced immune activation, transgene-related cellular stress, and delivery-associated tissue injury. However, direct evidence supporting antioxidant–gene therapy combinations remains predominantly preclinical, and their clinical efficacy has not yet been established. Disease- and stage-specific integration of antioxidants and redox modulation may help preserve viable retinal cells, support retinal homeostasis during genetic rescue, and potentially improve treatment durability.
Stargardt disease (STGD1) is the most common inherited macular dystrophy. It is caused by biallelic variants in the ABCA4 gene and leads to impaired retinoid transport within photoreceptors. Disruption of retinoid clearance results in the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which in turn...
T. Lipsky, Sophia Dithmar, G. Ansari et al.· Die Ophthalmologie· 0 citations
The hypothesis that simultaneous modulation of oxidative stress and neuroinflammation provides greater neuroprotective benefits provides greater neuroprotective benefits for RP is supported and GALR3 is identified as a promising therapeutic target.
Maria Azam, Ming-Da Liu, Beata Jastrzebska· Antioxidants· 1 citation
Current evidence supporting ferroptosis-related vulnerability in retinal neurodegenerative diseases is synthesized and emerging enabling strategies are evaluated, including nanocarrier-based delivery, long-acting gene modulation, and biomarker frameworks integrating ocular fluids, imaging, multi-omics, and artificial i...
Guang-Guang Wu, Su-Yu Wang, Zi-Yi Chen et al.· Frontiers in Medicine· 0 citations
A narrative review provides a comprehensive overview of the major stem cell sources investigated for retinal regeneration and the roles of extracellular vesicles and retinal organoids as emerging therapeutic platforms are discussed.
There is an increasing global burden of ocular disorders, with an estimated 43.3 million people worldwide currently blind and a further 295 million living with moderate-to-severe vision impairment, driven by a complex pathogenesis that involves multiple cascade failures ranging from mitochondrial dysfunction to chronic...
S. Tejeda, Sese-Owei Ekaye, Jean M. Taylor et al.· Life· 0 citations
This review uniquely integrates these molecular targets with appropriate animal models, providing a comprehensive strategic framework for translating genetic discoveries into clinical applications.
Ya-Qin Zhang, Xiao-Yu Dong, Cai-Yan Zheng et al.· Current Neuropharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.